Drugs / HKI-357
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00550381 Comparator | Jan → Mar 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HKI-357 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00550381 ↗ |
| Modality | Small molecule | — CHEMBL178654 ↗ |
| Route | Oral | “HKI-357 Administered Orally” NCT00550381 ↗ |